ASCO Boosts AstraZeneca’s Standings, And Options
This article was originally published in The Pink Sheet Daily
The firm’s head oncology strategist says positive data released at the American Society of Clinical Oncology was not included in financial forecasts provided a month ago while AstraZeneca fought off Pfizer’s takeover attempt.
You may also be interested in...
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.